title: Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance.
abstract: OBJECTIVE
  To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung.
  
  
  METHODS
  Paraffin wax sections of 93 patients with adenocarcinomas of the lung who underwent surgery between 1990 and 1995 were immunohistochemically investigated using monoclonal anti-CEACAM1 and sialyl Lewis X antibodies. The clinical course of all patients was followed up for a minimum of 5 years.
  
  
  RESULTS
  Sixty-one tumors were classified as CEACAM1-positive, and 32 were classified as CEACAM1-negative. Patients with CEACAM1-positive tumors had a significantly poorer overall (P =.00025) and relapse-free (P =.00029) survival than those with CEACAM1-negative tumors. Only three patients did not express the sialyl Lewis X glycotope, whereas 90 tumors (97%) were sialyl Lewis X-positive. In multivariate Cox regression analysis, next to tumor stage and sex, only the expression of CEACAM1 was a significant independent prognostic factor for survival.
  
  
  CONCLUSIONS
  Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity.
authors.affiliation: Department of Oncology and Hematology, Institute for Anatomy, University Hospital Hamburg-Eppendorf, Hamburg, Germany. laack@uke.uni-hamburg.de
authors.forename: Eckart
authors.initials: E
authors.lastname: Laack
authors.forename: Haleh
authors.initials: H
authors.lastname: Nikbakht
authors.forename: Anja
authors.initials: A
authors.lastname: Peters
authors.forename: Christian
authors.initials: C
authors.lastname: Kugler
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Jasiewicz
authors.forename: Lutz
authors.initials: L
authors.lastname: Edler
authors.forename: Jens
authors.initials: J
authors.lastname: Brümmer
authors.forename: Udo
authors.initials: U
authors.lastname: Schumacher
authors.forename: Dieter Kurt
authors.initials: DK
authors.lastname: Hossfeld
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis* / Q000096:biosynthesis*; D000943:Antigens, Differentiation / Q000032:analysis* / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology*; D015815:Cell Adhesion Molecules; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007983:Lewis Blood Group Antigens; D016256:Lewis X Antigen; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000032:analysis*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D000080506:Sialyl Lewis X Antigen; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D007983:Lewis Blood Group Antigens; D016256:Lewis X Antigen; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen